IPO - Profile

Bolt Biotherapeutics, Inc.

Health Care > Major Pharmaceuticals



We are a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Our proprietary Boltbody ISAC approach uses immunostimulants to engage and activate myeloid cells, including macrophages and dendritic cells, that directly kill tumor cells via phagocytosis and expose tumor neoantigens to the adaptive immune system. This leads to recruitment of cytotoxic T cells and additional tumor-killing myeloid cells thereby converting immunologically “cold” tumors to “hot” tumors. We believe that this process leads to the development of systemic immunological memory with epitope More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$20.00 11,500,000 Positive High 60.08%

Offering Team

  • Legal counsel
  • Cooley LLP
  • Auditors
  • PricewaterhouseCoopers LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 04 Feb, 2021

Offer 05 Feb, 2021

Look Ahead

Lock Up Expiry Aug 05, 2021

IPO Terms

Offer Price $20.00
Offer Size 11M

Market Sentiments

Stock Price